HHS — Lanton Law Blog

FTC, DOJ and HHS Extend RFI on Private Equity Control in Health Care Markets

The Federal Trade Commission, the Department of Justice’s (DOJ) Antitrust Division, and the U.S. Department of Health and Human Services (HHS) are extending the deadline by 30 days for the public to comment on a tri-agency Request for Information (RFI) examining private-equity and other corporations’ increasing control over health care markets. The new deadline is now June 5, 2024.

healthcare, hospitals, IoT, HealthIT, LTC, life sciences, Long term care pharmacy, pharmaceuticals, PhRMA, private equity, SPAC, technologyRon LantonMay 2, 2024private equity firms, private equity, FTC, HHS, DOJ, RFI

Biden Administration Announces First Ten Drugs Selected for Medicare Price Negotiation

The Biden Administration has announced today that Medicare will be able to negotiate drug prices for the first time due to provisions within the Inflation Reduction Act.

healthcare, life sciences, Medicare Part D, pharmaceuticals, prescription drug costsRon LantonAugust 29, 2023Inflation Reduction Act, drug prices, pharmaceuticals, prescription drug prices, Medicare Part D, CMS, HHS

NCPA Files Lawsuit on Pharmacy Direct & Indirect Remuneration (DIR) Fees

The National Community Pharmacists Association (NCPA) has filed a lawsuit against the U.S. Department of Health & Human Services (HHS) on DIR fees. Specifically, the complaint seeking declaratory and injunctive relief seeks three things according to NCPA’s release:

pharmacy, pharmaceuticals, pharmacy benefit manager, Medicare, Medicare Part D, lawsuits, healthcare, insurance, HHSRon LantonJune 7, 2021Pharmacy, U.S. Department of Health & Human Services, DIR fee, direct and indirect remuneration fees, HHS, federal court, law, lawsuit

HHS Delays Rebate Rule to 2023 Due to a Court Order

Health and Human Services (HHS) has announced that the Trump administration’s directive that would have implemented the drug rebate rule against pharmacy benefit managers (PBMs).

healthcare, HHS, pharmaceuticals, physician, pharmacy benefit manager, prescription drug costsRon LantonMarch 18, 2021Drug Rebate Rule, Pharmacy Benefit Manager, Health and Human Services, HHS, U.S. District Court for the District of Columbia

New Executive Order Aimed at Pharmacy Benefit Managers (PBMs)

The White House has released an Executive Order titled “Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen.”

reimbursement, prescription drug costs, pharmacy benefit manager, pharmacy, pharmaceuticals, Medicare Part D, insurance, HHS, life sciences, healthcareRon LantonJuly 27, 2020Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen, PBM, Pharmacy Benefit Manager, safe harbor, Medicare D, Medicaid, HHS

White House Issues Executive Order Advocating for Importation

The White House has issued an Executive Order titled “Executive Order on Increasing Drug Importation to Lower Prices for American Patients,” which seeks to advocate for having supply chain entities proceed with importation.

drug price, HHS, importation, life sciences, pharmaceuticals, pharmacy, reimbursementRon LantonJuly 27, 2020drug price, Executive Order on Increasing Drug Importation to Lower Prices for American Patients, importation, Canada, HHS

The Administration Releases Executive Order Targeting Insulin and Injectable Epinephrine via 340B

The White House has announced a few Executive Orders targeting healthcare. One Executive Order titled Executive Order on Access to Affordable Life-saving Medications targets insulin and injectable epinephrine by requiring federally qualified community health centers to pass through 340B program discounts to patients using insulin and epinephrine auto-injectors.

HHS, life sciences, pharmaceuticals, pharmacy, reimbursement, hospitals, drug priceRon LantonJuly 27, 2020340B, insulin, epinephrine, HHS, FQHC, insurance, Executive Order on Access to Affordable Life-Saving Medications